XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing...

Benzinga

2026.10.19 13:03 (GMT+0)

Abrir em Benzinga